Roche, big data and patient outcomes: the pharmaphorum podcast
January 8, 2020
In the first pharmaphorum podcast of 2020 Roche’s Conor Megaw talks about his company’s approach to big data
Pfizer and the UK cancer landscape: the pharmaphorum podcast
December 11, 2019
Pfizer’s Dr Olivia Ashman joined me for episode 16 of the pharmaphorum podcast, which focuses on the UK
Life sciences leadership: the pharmaphorum podcast
November 14, 2019
Episode 15 of the pharmaphorum podcast marked a return visit for leading life sciences industry authority Professor Brian
AstraZeneca and lung cancer: the pharmaphorum podcast
August 7, 2019
This episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, Global Franchise Head, Tagrisso TDR
Lung cancer’s patient information gap: the pharmaphorum podcast
August 6, 2019
For episode 13 of the pharmaphorum podcast I went to AstraZeneca’s London base to meet Paul Naish, who’s
The state of UK drug discovery: the pharmaphorum podcast
July 19, 2019
The UK environment for drug discovery, the impact of artificial intelligence (AI) on medicines research and the role of complex cell models were all on the agenda for episode 12 of the pharmaphorum podcast.
On it I spoke with Chris Molloy, who’s CEO at the UK’s Medicines Discovery Catapult, about the Catapult’s State of the Discovery Nation publication, a joint report with the UK’s biotech trade body the BioIndustry Association.
Addressing global health challenges: the pharmaphorum podcast
June 19, 2019
For episode 11 of the pharmaphorum podcast our CEO and founder Dr Paul Tunnah took the helm to record a special roundtable episode in Philadelphia with the International AIDS Vaccine Initiative (IAVI).
Gene therapy and market access: the pharmaphorum podcast
May 31, 2019
For episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio in the UK.
The Cambridge, Massachusetts-based company has gone from being a gene therapy start-up to having three potential blockbusters on its books, with a CAR-T cancer medicine and potential treatments for a type of sickle-cell disease and a rare and deadly genetic brain disease.
AMR research and Matoke Pharma: the pharmaphorum podcast
May 13, 2019
Re-engineered honey has proved to be a novel and successful development for Matoke Pharma, as well as a crucial step on the UK biotech company’s plans to target antimicrobial resistance (AMR).
In episode 9 of the pharmaphorum podcast Alan Westwood explains the research behind Matoke’s SurgihoneyRO, an antimicrobial wound gel that has a CE mark in Europe, and how the company is taking that product’s reactive oxygen (RO) component to develop novel pharmaceutical antimicrobials.
GSK and digital disruption: the pharmaphorum podcast
April 5, 2019
Digital innovation and disruption in healthcare are the subject of this episode of the pharmaphorum podcast, for which I visited GlaxoSmithKline at their Stockley Park base to speak with Kai Gait, a senior global digital strategy director at the company.
Ipsen on neurotoxin research: the pharmaphorum podcast
March 28, 2019
For episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a particular focus on Botulinum neurotoxins.
